FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Didier Pélaprat

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Anatomy

Physiology

Co-author Network

Publications

TOP 3
Klára Felszeghy; José Manuel Espinosa; Hélène Scarna; Anne Bérod; William Rostène; Didier Pélaprat
Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference.
Olivier Raguin; Marie-Claude Fournié-Zaluski; Anthony Romieu; André Pèlegrin; François Chatelet; Didier Pélaprat; Jacques Barbet; Bernard P Roques; Anne Gruaz-Guyon
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis.
Karen T Delle Donne; June Chan; Helene Boudin; Didier Pélaprat; William Rostène; Virginia M Pickel
Electron microscopic dual labeling of high-affinity neurotensin and dopamine D2 receptors in the rat nucleus accumbens shell.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Didier Pélaprat (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Klára Felszeghy; José Manuel Espinosa; Hélène Scarna; Anne Bérod; William Rostène; Didier Pélaprat
Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(12):2601-10.
2005: Olivier Raguin; Marie-Claude Fournié-Zaluski; Anthony Romieu; André Pèlegrin; François Chatelet; Didier Pélaprat; Jacques Barbet; Bernard P Roques; Anne Gruaz-Guyon
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis.
Angewandte Chemie (International ed. in English) 2005;44(26):4058-61.
2004: Karen T Delle Donne; June Chan; Helene Boudin; Didier Pélaprat; William Rostène; Virginia M Pickel
Electron microscopic dual labeling of high-affinity neurotensin and dopamine D2 receptors in the rat nucleus accumbens shell.
Synapse (New York, N.Y.) 2004;52(3):176-87.
2004: Patrick Kitabgi; Didier Pélaprat
Characterization of neurotensin receptors.
Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] 2004;Chapter 1():Unit 1.29.
2004: Mireille Toy-Miou-Leong; Claude-Marie Bachelet; Didier Pélaprat; William Rostène; Patricia Forgez
NT agonist regulates expression of nuclear high-affinity neurotensin receptors.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2004;52(3):335-45.
2002: Ghazal Banisadr; F Quéraud-Lesaux; M C Boutterin; Didier Pélaprat; Bernard Zalc; William Rostène; France Haour; Stéphane Mélik Parsadaniantz
Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain.
Journal of neurochemistry 2002;81(2):257-69.
2001: Antony Lebeau; F Esclaire; William Rostène; Didier Pélaprat
Baicalein protects cortical neurons from beta-amyloid (25-35) induced toxicity.
Neuroreport 2001;12(10):2199-202.
2001: Virginia M Pickel; June Chan; Karen T Delle Donne; Helene Boudin; Didier Pélaprat; W Rosténe
High-affinity neurotensin receptors in the rat nucleus accumbens: subcellular targeting and relation to endogenous ligand.
The Journal of comparative neurology 2001;435(2):142-55.
2000: Helene Boudin; B Lazaroff; Claude-Marie Bachelet; Didier Pélaprat; William Rostène; Alain Beaudet
Immunologic differentiation of two high-affinity neurotensin receptor isoforms in the developing rat brain.
The Journal of comparative neurology 2000;425(1):45-57.
2000: I Lépée-Lorgeoux; C Betancur; Frédérique Souazé; William Rostène; Anne Bérod; Didier Pélaprat
Regulation of the neurotensin NT(1) receptor in the developing rat brain following chronic treatment with the antagonist SR 48692.
Journal of neuroscience research 2000;60(3):362-9.
1999: I Lépée-Lorgeoux; C Betancur; William Rostène; Didier Pélaprat
Differential ontogenetic patterns of levocabastine-sensitive neurotensin NT2 receptors and of NT1 receptors in the rat brain revealed by in situ hybridization.
Brain research. Developmental brain research 1999;113(1-2):115-31.
1998: Helene Boudin; Didier Pélaprat; William Rostène; Virginia M Pickel; Alain Beaudet
Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1998;18(20):8473-84.
1998: C Betancur; R Cabrera; Ron de Kloet; Didier Pélaprat; William Rostène
Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(4):322-32.
1998: C Betancur; M Canton; A Burgos; B Labeeuw; Danielle Gully; William Rostène; Didier Pélaprat
Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.
European journal of pharmacology 1998;343(1):67-77.
1997: Claude-Marie Bachelet; V Scarcériaux; William Rostène; Didier Pélaprat
Evidence for neurotensin autoreceptors and relationship of neurotensin and its receptors with tyrosine hydroxylase-positive neurons in rat primary hypothalamic cultures.
The European journal of neuroscience 1997;9(7):1483-7.
1996: M Azzi; Helene Boudin; N Mahmudi; Didier Pélaprat; William Rostène; Anne Bérod
In vivo regulation of neurotensin receptors following long-term pharmacological blockade with a specific receptor antagonist.
Brain research. Molecular brain research 1996;42(2):213-21.
1996: Helene Boudin; Didier Pélaprat; William Rostène; Alain Beaudet
Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor.
The Journal of comparative neurology 1996;373(1):76-89.
1996: V Scarcériaux; Frédérique Souazé; C M Bachelet; Patricia Forgez; E Bourdel; J Martinez; William Rostène; Didier Pélaprat
Neurotensin receptor down-regulation induced by dexamethasone and forskolin in rat hypothalamic cultures is mediated by endogenous neurotensin.
Journal of neuroendocrinology 1996;8(8):587-93.
1996: Helene Boudin; J Labrecque; Anne-Marie Lhiaubet; M Dennis; William Rostène; Didier Pélaprat
Pharmacological and molecular characterization of the neurotensin receptor expressed in Sf9 cells.
Biochemical pharmacology 1996;51(9):1243-6.
1996: F Maignen; Patrick Tilleul; C Billardon; W Y Xu-Van Opstal; Didier Pélaprat; P P Elena; P Denis; William Rostène
Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1996;12(3):289-98.
1995: C Betancur; M Canton; D Gully; G Vela; Didier Pélaprat; William Rostène
Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1450-8.
1995: V Scarcériaux; Didier Pélaprat; Patricia Forgez; Anne-Marie Lhiaubet; William Rostène
Effects of dexamethasone and forskolin on neurotensin production in rat hypothalamic cultures.
Endocrinology 1995;136(6):2554-60.
1994: V Scarcériaux; Didier Pélaprat; Patricia Forgez; Anne-Marie Lhiaubet; William Rostène
Effect of dexamethasone and forskolin on neurotensin expression in hypothalamic cells in culture.
Annals of the New York Academy of Sciences 1994;746():476-9.
1994: V Scarériaux; Didier Pélaprat; Anne-Marie Lhiaubet; RM Schimpff; G Tramu; William Rostène
Developmental pattern of neurotensin content in rat hypothalamic neurons cultured in serum-free medium: comparison with in vivo data.
Brain research. Developmental brain research 1994;81(1):128-30.
1994: M Azzi; D Gully; M Heaulme; Anne Bérod; Didier Pélaprat; Patrick Kitabgi; R Boigegrain; Jean-Pierre Maffrand; G LeFur; William Rostène
Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists.
European journal of pharmacology 1994;255(1-3):167-74.
1992: Y Masuo; H Wang; Didier Pélaprat; Z Q Chi; William Rostène
Effect of brain lesions on [3H]ohmefentanyl binding site densities in the rat striatum and substantia nigra.
Chemical & pharmaceutical bulletin 1992;40(9):2520-4.
1991: H Wang; A Sarrieau; Didier Pélaprat; B P Roques; A Vanhove; N Kopp; Z Q Chi; W Rostène
Characterization and distribution of [3H]ohmefentanyl binding sites in the human brain.
Synapse (New York, N.Y.) 1991;8(3):177-84.
1991: H Wang; Didier Pélaprat; B P Roques; A Vanhove; Z Q Chi; William Rostène
[3H]ohmefentanyl preferentially binds to mu-opioid receptors but also labels sigma-sites in rat brain sections.
European journal of pharmacology 1991;193(3):341-50.
1990: Y Masuo; Didier Pélaprat; D Scherman; William Rostène
[3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum.
Neuroscience letters 1990;114(1):45-50.
1990: Y Masuo; M N Montagne; Didier Pélaprat; D Scherman; William Rostène
Regulation of neurotensin-containing neurons in the rat striatum. Effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density.
Brain research 1990;520(1-2):6-13.
1990: Y Masuo; Didier Pélaprat; M N Montagne; D Scherman; William Rostène
Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
Brain research 1990;510(2):203-10.
1989: I Marseigne; P Roy; A Dor; C Durieux; Didier Pélaprat; Michel Reibaud; J C Blanchard; Bernard P Roques
Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue.
Journal of medicinal chemistry 1989;32(2):445-9.
1988: C Durieux; Didier Pélaprat; B Charpentier; J L Morgat; Bernard P Roques
Characterization of [3H] CCK4 binding sites in mouse and rat brain.
Neuropeptides 1988;12(3):141-8.
1988: I Marseigne; A Dor; D Bégué; Michel Reibaud; J L Zundel; J C Blanchard; Didier Pélaprat; Bernard P Roques
Synthesis and biological activity of CCK26-33-related analogues modified in position 31.
Journal of medicinal chemistry 1988;31(5):966-70.
1987: Didier Pélaprat; Y Broer; Jeanne-Marie Studler; Marc Peschanski; Jean-Pol Tassin; J Glowinski; W Rostène; Bernard P Roques
Autoradiography of CCK receptors in the rat brain using [(3)H]Boc[Nle(28)(31)]CCK(27)-(33) and [(125)I]bolton-hunter CCK(8). Functional significance of subregional distributions.
Neurochemistry international 1987;10(4):495-508.
1985: Didier Pélaprat; J M Zajac; G Gacel; C Durieux; J L Morgat; A Sasaki; Bernard P Roques
[3H] Boc [Nle28, 31]CCK27-33, a new highly labelled ligand for CCK receptors: binding on brain and on pancreas.
Life sciences 1985;37(26):2483-90.
1985: Bernard P Roques; C Durieux; G Gacel; Didier Pélaprat; Mariano Ruiz-Gayo; J Belleney; E Fellion; J M Zajac; Marie-Claude Fournié-Zaluski; Valérie Daugé
Studies on the conformation, enzymatic degradation, pharmacological potency, and binding properties in brain tissue of cholecystokinin-8 and new related peptides.
Annals of the New York Academy of Sciences 1985;448():61-75.